Central cholinergic antinociception induced by 5HT4 agonists: BIMU 1 and BIMU 8 by Ghelardini, Carla et al.
ELSEVIER 
Life sciences, Vol. 58, No. 25, pp. 2297-23’9,19% 
CoWright 0 1% @kvier science Inc. 
printed in the USA. All rights ~~ 
PII SOO24-3205(96)00230-S o&24-3205/% tls.00 + 00 
CENTRAL CHOLINERGIC ANTINGCICEPTION INDUCED BY 5HT4 
AGONISTS: BIMU 1 AND BIMU 8 
Carla Ghelardini, Nicoletta Galeotti, Fiorella Casamenti, Petra Mahnberg-Aiello, Giancarlo 
Pepeu, *Fulvio Gualtieri and Alessandro Bartolini 
Departments of Preclinical and Clinical Pharmacology, Viale G.B. Morgagni 65, I-50134 
Florence and *Pharmaceutical Sciences, Via G. Capponi 9, I-50121 Florence, Italy 
(Received in final form April 17, 19%) 
The antinociceptive effect of two 5-HT4 agonists, BIMU 1 and BIMU 8, were 
examined in mice and rats by using the hot-plate, abdominal constriction and paw- 
pressure tests. In both species, BIMU 1 (lo-20 mg kg-’ s.c.and 40-60 mg kg-’ 
p.o. in mice; 20 mg kg-t i.p. in rats) and BIMU 8 (20-30 mg kg-’ S.C. and 60 mg 
kg-’ p.o. in mice; 20 mg kg-’ i.p. in rats), produced significant antinociception 
which was prevented by atropine (5 mg kg-’ i.p.), hemicholinium-3 (1 pg per 
mouse i.c.v.), SDZ 205-557 (10 mg kg-’ i.p.), GR 125487 (20 mg kg-’ i.p.) but 
not by naloxone (1 mg kg“ i.p.). CGP 35348 (100 mg kg-’ i.p.) and reserpine (2 
mg kg-’ i.p.). Moreover, BIMU 1 and BIMU 8 increase of pain threshold, is 
abolished by nucleus basalis magnocellularis (NBM) lesions in rats. SDZ 205-557 
and GR 125487 which totally antagonized BIMU 1 and BIMU 8 antinociception 
did not modify morphine (7 mg kg-’ s.c.) or baclofen (4 mg kg-’ s.c.) 
antinociception. Intracerebroventricular injection in mice of BIMU 1 (3 pg per 
mouse) and BIMU 8 (10 pg per mouse), doses which were largely ineffective by 
parenteral routes, induces an antinociception whose intensity equaled that 
obtainable s.c., i.p. or p.o. In the antinociceptive dose-range, neither 5HT4 
agonist impaired mice motor coordination evaluated by rota-rod test. On the basis 
of the above data, it can be postulated that BIMU 1 and BIMU 8 exerted an 
antinociceptive effect mediated by a central amplification of cholinergic 
transmission. 
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The stimulation of adenylate cyclase by 5HT4 agonists triggers a cascade of cellular events thought 
to lead to the release of neurotransmitters uch as acetylcholine (ACh) (1). 5HT4 agonists are able 
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to stimulate guinea-pig ileum motility through activation of intramural cholinergic nerve pathways 
subserving peristalsis (2, 3) since this effect is abolished by antimuscarinic treatment (3). BIMU 1 
and BIMU 8 are two benzimidazolone derivatives which exhibit 5HT4 ago&tic properties (4,5). 
These two compounds are endowed not only with the ability to potentiate electrically stimulated 
twitch responses in guinea-pig ileum longitudinal (6) and circular muscle (3), but also to stimulate 
the contractility of the gastric pouch in conscious dogs (7,8) and detrusor muscle in human (9). 
Moreover, BIMU 1 and BIMU 8 facilitate in vivo ACh release in the frontal cortex of rats as 
shown by microdialysis studies (IO). This facilitatory effect was blocked by the selective 5HT4 
antagonists GR 125487 and GR 113808 indicating, therefore, that this potentiation of ACh release 
is mediated by 5HT4 receptors. It has long been known that ACh (11). selective Ml agonists such 
as McN-A-343 and AF-102B (12), unselective muscarinic agonists such as tremorine (13), 
oxotremorine (14, 15), arecoline (16), pilocarpine (17) and cholinesterase inhibitors such as 
physostigmine (18, 19) and diisopropyl phosphorofluoridate (20) induce antinociception in 
laboratory animals by the activation of the cholinergic system. Moreover, the amplification of 
cholinergic neurotransmission induced by antagonism of muscarinic autoreceptors (2 1, 22, 23) 
or, alternatively, by interaction with heteroreceptors (24) located on presynaptic cholinergic 
terminals, produces a central antinociceptive effect. In the present work, the ability of BIMU 1 
and BIMU 8 for modifying pain hreshold was investigated. 
Methods 
Animals 
Male Swiss albino mice (23-30 g) and Wistar rats (200-300 g) from the Morini breeding farm 
were used. Fifteen mice and four rats were housed per cage. The cages were placed into the 
experimental room 24 h before the test for acclimatization. The animals were kept at 23fl ‘C with 
a 12 h light/dark cicle, light at 7 a.m., with food and water ad libitum. Animals were randomly 
assigned to a control (saline solution) or a treated group (BIMU 1 - BIMU 8). Both groups 
received a pretreatment consisting in the injection of one of the following antagonists: atropine, 
naloxone, SD2 205-557, GR 125487, hemicholinium-3 (HC-3), CGP-35348 or reserpine. All 
the antagonists were injected 15 min before treatment with the exception of HC-3, CGP 35348 and 
reserpine. HC-3 and CGP-35348 were administered respectively 5 h and 5 min before treatment 
whereas reserpine was injected twice, 48 and 24 h, before the test. All animals used were drug 
naive. All experiments were carried out according to the guidelines of the European Community 
Council. 
Hot nlate test 
The method adopted was described by O’Callaghan and Holtzman (25). Mice were placed inside a 
stainless steel container, thermostatically set at 52.5 + 0.1 “C in a precision water-bath from KW 
Mechanical Workshop, Siena, Italy. Reaction times (s), were measured with a stop-watch about 
30 min before pretreatment (pretest) and 15, 30 and 45 min after treatment. The endpoint used 
was the licking of the fore or hind paws. Those mice scoring below 12 and over 18 s in the pretest 
were rejected (30%). An arbitrary cut-off time of 45 s was adopted at which the animals were 
removed from the hot-plate and given a score of 45 s. 
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Abdominal constriction test 
The test was performed in mice according to Koster et al. (26). Mice were injected i.p. with a 
0.6% solution of acetic acid (10 ml kg-l). The number of stretching movements was counted for 
10 min, starting 5 min after acetic acid injection. Both BIMU 1 and BIMU 8 were administered 10 
n-tin before acetic acid injection. 
Paw uressure 
The nociceptive threshold in the rat was determined with an analgesimeter (Ugo Basile, Varese, 
Italy), according to the method described by Leighton et al. (27). Threshold pressure was 
measured about 30 min before treatment (pretest) and 15, 30 and 45 min after treatment. Rats 
scoring below 50 g or over 85 g during the pretest were rejected (25%). An arbitrary cut-off value 
of 250 g was adopted. 
Rota-rod test 
The apparatus consisted of a base platform and a rotating rod of 3 cm diameter with a non-slippery 
surface. This rod was placed at height of 15 cm from the base. The rod, 30 cm in length, was 
divided into 5 equal sections by 6 disks. Thus up to 5 mice were tested simultaneously on the 
apparatus, with a rod-rotating speed of 16 r.p.m. The integrity of motor coordination was 
assessed on the basis of the number of falls from the rod in 30 s according to Vaught et al. (28). 
The performance time was measured before and 15,30 and 45 min after treatment. 
Nucleus basalis magnocellularis lesions 
Under ketamine anaesthesia (100 mg kg-’ i.p.) bilateral lesions of the rat nucleus basalis 
magnocellularis (NBM) were made by stereotaxic injection of 0.5 ~1 of 0.12 M quisqualic acid 
dissolved in 50 mM sodium phosphate buffer (pH=7.4) with a 10 l.tl Hamilton syringe. The 
injection lasted 3 min and the syringe was left in position for 5 min after the completion of the 
infusion. The following coordinates, taken from Paxinos and Watson (29) stereotaxic atlas, were 
used: 0.5 mm posterior to bregma, 2.8 mm lateral, 6.8 mm below dura. Twenty days after 
surgery the weight of the rats was only slightly below that of controls and they looked healthy. In 
the sham-operated rats the syringe needle was lowered into the cortex and no quisqualic acid was 
injected. At the end of the experiments the location and size of the lesions were checked by 
histological examination on 10 l.trn-thick slices stained with the cresyl violet according to the Nissl 
method. 
. . 
Choline acetvltransferase determtnauo n 
After completing the behavioural paw-pressure test, lesioned and sham operated rats were 
decapitated. Brains were then removed and cortexes dissected out. Choline acetyltransferase 
activity was determined according to the method of Fonnum (30). 
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The following drugs were used: BIMU 1 (endo-N-(B-methyl-B-azabicyclo[3.2.1]-oct-3-y1)-2,3- 
dihydro-3-ethyl-2-oxo-lH-benzimidazol-l-carboxamide hydrochloride), BIMU 8 (endo-N-(l- 
methyl-8-azabicyclo[3.2.1]-oct-3-yl)-2,3-dihydro-(l-methyl)ethyl-2-oxo-lH-~nzi~d~l-l car- 
boxamide hydrochloride) and GR 125487 ([ l-[2(methylsuphonyl)amino]ethyl]4-piperidinyl] 
methyl- 5- fluoro - 2-methoxy-lH-indole-3-carboxylate hydrochloride) (Boehringer Ingelheim, 
Italy), atropine sulphate, baclofen and quisqualic acid (Sigma, USA), hemicholinium-3 
hydrobromide (HC-3) and naloxone hydrochloride (RBI), SDZ 205557 (2-methoxy-4-amino-5- 
chlorobenzoic acid 2-(diethylamino) ethyl ester hydrochloride) was prepared in the Department of 
Pharmaceutical Sciences of University of Florence according to the method described by 
Romanelli et al. (31), morphine hydrochloride (Carlo Erba, Italy), CGP 35348 (3-aminopropyl- 
diethoxymethyl-phosphinic acid), ascorbic acid and reserpine (Ciba Geigy, Switzerland), sodium 
chloride and acetic acid glacial (Merck), sodium carboxymethylcellulose (Fluka, Switzerland). All 
drugs were dissolved in isotonic (NaCl 0.9 %) saline solution or dispersed in sodium 
carboxymethylcellulose 1% immediately before use except reset-pine which was dissolved in a 
20% solution of ascorbic acid. Drug concentrations were prepared in such a way that could be 
administered in a volume of 10 ml kg-’ by subcutaneous (s.c.), intraperitoneal (i.p.) and per OS 
(p.0.) route. Intracerebroventricular (i.c.v.) administration was performed under ether anaesthesia 
using isotonic saline as solvent, according to the method described for mice by Haley and 
McCormick (32) and extended for rats by us. Substances were injected in the necessary dose 
dissolved in 5 pl for mice and 10 pl for rats. To ascertain the exact point into which the drugs 
were administered, some mice or rats were injected i.c.v. with 5 or 10 pl of diluted 1:lO Indian 
ink and their brains were examined macroscopically after sectioning. 
Statistical analysis: Results are given as the mean f s.e.m.; analysis of variance, followed by 
Scheffe’s F procedure for post-hoc comparison, was used to verify significance between two 
means. P values of less than 0.05 were considered significant. Data were analyzed with computer 
program (StatView for the Macintosh, 1992). 
The antinociceptive effect of BIMU 1 and BIMU 8 was investigated on the hot-plate and 
abdominal constriction tests in mice and on the paw pressure test in rats. In the hot-plate test, 
BIMU 1 and BIMU 8, injected i.p. in the range of doses of lo-20 mg kg-’ and 20-30 mg kg-’ 
respectively, induced a significant increase in the pain threshold (Fig. 1 - panel A and B). The 
antinociceptive effect reached a maximum 15 min after administration and then diminished, 
disappearing within 45 min. Table 1 shows that BIMU 1 and BIMU 8 antinociception was 
completely prevented by the antimuscarinic drug atropine (5 mg kg-’ i.p.), the choline uptake 
blocker HC-3 (1 pg per mouse i.c.v.) and both 5-HT4 antagonists SDZ 205-557 (10 mg kg-’ 
i.p.) and GR 125487 (20 mg kg-’ i.p.). Conversely, no modification in B&J 1 and BIMU 8 
antinociception was obtained by pretreating mice with the opioid antagonist naloxone (1 mg kg-’ 
i.p.) and the GABAn antagonist CGP 35348 (100 mg kg-’ i.p.). Fig. 2 shows that the doses of 
10 mg kg-* i.p. and 20 mg kg-’ i.p. of SDZ 205-557 and GR 125487 respectively were needed 
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Fig. 1 
Dose response curves of BIMU 1 (panel A) and BIMU 8 (pa- 
nel B) in the mouse hot-plate test. 
The doses are expressed as mgkg-l i.p.. Vertical lines show s.e. 
mean. APc 0.05; * P c 0.01 in comparison with saline controls. 
Each point represents the mean of at least 10 mice. 
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TABLE 1 
Effects of atro 
caused by B d 
ine, HC-3 naloxone, CGP-35348, SDZ-205557 and GR 125487 on antinociception 
U 1 and BiMU 8 in the mouse hot-plate test. 
Licking latency (s) 
mg-kg-* Before 
S.C. pretreatment 15 min 
Aftertr%z.a.t Pretreatment 
Saline 
10 ml-kg-1 i.p. 
Saline 
5 pl i.c.v. 
Saline 
i.p. or i.c.v. 
HC-3 
1 pg per mouse 
i.c.v. 
Naloxoq 
1 mg*kg- 
1.p. 
CGP 35348 
jO0 mg-kg-* 
1.p. 
SDZ-2055p7 
10 mg*kg- 
1.p. 
Treatment 
Saline 
Saline 
BIMU 1 
BIMU 8 
Saline 
BIMU 1 
BIMU 8 
Saline 
BIMU 1 
BIMU 8 
Saline 
BIMU 1 
BIMU 8 
Saline 
BIMU 1 
BIMU 8 
Saline 
BIMU 1 
BIMU 8 
Saline 
BIMU 1 
BIMU 8 
20 
30 
20 
30 
20 
30 
20 
30 
20 
30 
20 
30 
20 
30 
13.6M.7 
14.1ti.9 
14.4kl.O 13.9fl.9 14.3M.8 
13.9zb1.2 13.3ti.9 14.tkb1.2 
14.m.9 
13.5fl.l 
26.4*1.8* 23.7f1.6* 16.31t1.6 
24.3+1.7* 22.5f1.5* 17.1f1.3 
14.0.7 13.3k1.3 13.1kl.l 14.2k1.3 
14.2kl.O 16.7f1.8’ 16.1&2.2” 15.M1.8 
13.851.1 16.1ti.l” 15.9&1.9° 14.2k1.7 
14.4ti.9 
13.Wl.l 
14.011.2 
13.8k1.5 15.5f1.3 15.4k1.2 
17. lX!.o” 16.6k1.9’ 14.W1.5 
16.6k1.8O 17.6k1.7’ 15.4fl.2 
13.5ti.8 
13.8M.7 
14.1ti.9 
14.ti1.5 13.ti1.6 14.3k1.7 
27.1ti.3* 24.7&2.3* 18.3ti.4 
26.1+1.7* 25.1%2.1* 17.8f1.8 
13.5M.7 
14.4H.8 
13.8fl.O 
11.4*1.3* 12.5f2.0 12.7f1.5 
25.5&1.8* 23.8&2.2* 16.M1.6 
22.3&2.3* 20.6k2.3” 15.5k1.8 
14.2kl.O 
13.2ti.9 
14.2zh1.3 
15.1f1.8 14.5k1.6 14.8ti.O 
17.W.2’ 17.lf1.9O 16.5ti.l 
16.6k1.7’ 15.6ti.2’ 14.4k1.7 
13.8kl.l 
14.4zt1.2 
13.7kl.O 
14.0rt1.8 14.5rt1.8 16.5k1.4 
17.3f1.5O 17.2&2.0’ 15.4ziz1.9 
16.5f1.7’ 16.7k2.1’ 14.1f1.8 
45 min 
The num$r of mice is shown in parentheses. 
ne-saline. 
* P< 0.01. A P < 0.05 in comparison with sali- 
PC 0 01 versus saline-BIMU 1 or saline-B&III 8 treated mice. 
The number of mice ranged from 8-26 with the exception of saline-saline were n = 28-30. 
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Fig. 2 
Effect of SDZ-205557 (panel A) and GR-125487 (panel B) administered i.p. on an- 
tinociception induced by BIMU 1 (20 mg k 
ne (7 mg kg-’ s.c.) and baclofen (4 mg kg- 5 
-I), BIMU 8 (30 mg kg-’ s.c.), morphi- 
s.c.) in the mouse hot-plate test. SDZ- 
205557 and GR- 125487 were injected i.p. 15 min before BIMU 1 and BIMU 8 and 5 
min before morphine and baclofen. Nociceptive responses were recorded 15 min af- 
ter BIMU 1 and BIMU 8 administration and 30 min after morphine and baclofen in- 
jections. Numbers inside the columns indicate the number of mice. Vertical lines 
show s.e. mean. “PC 0.05; * PC 0.01 in comparison with saline controls. ’ PC 0.01 
versus BIMU 1 or BIMU 8 treated mice. 
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r- I 
SALINE RESERPINE 
pg i.c.v. 1 3 3 10 
Saline BlMU I BIMU 8 
mg kg“ p. ct. 40 60 60 
Saline BIMU 1 BIMU 8 
Fig. 3 
Dose-response curve of BIMU 1 and BIMU 8 administered S.C. (panel A), i.c.v. 
(panel B) and p. o. (panel C) in the mouse abdominal constriction test and lack of 
effect by reset-pine (2 mgkg-’ i.p.) pretreatment on BIMU 1 and BIMU 8 induced 
antinociception (panel A). 
Reserpine was injected twice 48 and 24 h before test. Vertical lines show s.e. mean. 
APc 0.05; * PC 0.01 in comparison with saline controls. The nociceptive response 
was recorded 15-25 min after BIMU 1 and BIMU 8 administration. Numbers inside 
the columns indicate the number of mice. 
Vol. 58, No. 25, 19% Antinociception by BIMU 1 and BIMU 8 
TABLE 2 
Effect of BIMU 1 and BIMU 8 in comparison with morphine in rats with and without 
bilateral lesions of the nucleus basalis magnocellularis tested in the rat paw pressure test 
2305 
Treatment 
ip. 
Before 
treatment 
Saline 10 ml kg-’ 
Naive (x) 66.6k3.4 
Sham 60.4k4.0 
Lesioned 64.7k4.2 
BIMU 1 20 mg kg-l 
Naive 69.5f3.9 
Sham 68.4fi.3 
Lesioned 71.2zb3.6 
BIMU 8 20 mg kg-’ 
Naive 66.4k3.4 
Sham 60.8k4.8 
Lesioned 64.3k3.6 
Morphine 5 mg kg-’ 
Naive 63.5b4.0 
Sham 62.4f3.4 
Lesioned 69.3k3.4 
PAW-PRESSURE (g) 
Afrer treatment 
15 min 30 min 45 min 
67.5k2.4 63.4k3.2 64.4zk3.4 
62.81k4.2 59.4k4.2 60.6k3.6 
65.4k3.8 60.4k4.6 58.3f3.8 
112.5ti.O* 75.W4.0 
121.3*4.7* 77.4rt5.2 
79.2f4.3’ 72.5k4.5 
64.0k4.2 
62.3k4.8 
67.Ckk3.8 
105.ti3.8* 94.6zb4.8” 
116.3&5.6* 102.4*4.8* 
70.5f4.0° 62.8f4.2’ 
68.6k4.2 
71.2ti.6 
65.4k3.8 
88.4fi.4” 133.0&5.1* 
92.3&4.5* 152.4&4.9* 
92.4&4.5* 138.4%.1* 
128.6k5.0* 
139.5k5.2* 
147.4&X8* 
The number of rats ranged from 6-9 with the exception of (x) where n = 13. 
“PC 0.05; * PcO.01 in comparison with saline control.“P< 001 in comparison with the 
corresponding sham operated rats. 
to completely antagonize the antinociception induced by the 5-IIT4 agonists BIMU 1 and BIMU 8 
without interfering in any way with morphine (7 mg kg-’ s.c.) and baclofen (4 mg kg-’ s.c.) 
evoked analgesia. The dose-response curve of BIMU 1 and BIMU 8 administered s.c., i.c.v. 
and p.o. on the abdominal constriction test is shown in Fig. 3. BIMU 1 and BIMU 8 exhibit in 
this test an antinociceptive effect independently of the administration route. The reduction of 
number of abdominal constrictions caused by BIMU 1 (20 mg kg-’ s.c.) and BIMU 8 (30 mg kg- 
1 s.c.) was not prevented by pretreatment with mserpine (2 mg kg-r i.p.>, a monoamine store 
depletor (Fig. 3). As shown in Table 2, BIMU 1 and BIMU 8 antinociception was confirmed in 
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TABLE 3 
Effect of BIMU 1 and BIMU 8 in the mouse rota-rod test. 
Treatment Dose Before 
pretreatment 
Saline 10 ml-kg-1 S.C. 
BIMU 1 10 mg-kg-’ S.C. 
BIMU 1 20 mgkg-’ S.C. 
BXMU 1 30 mg*kg“ S.C. 
BIMU 8 20 mg*kg“ S.C. 
BIMU 8 30 mg-kg-’ S.C. 
BIMU 8 40 mgkg“ S.C. 
Saline 
BIMU 1 
BIMU 1 
BIMU 8 
BIMU 8 
5 j.tl i.c.v. 
3 l.tl i.c.v. 
10 ll.1 i.c.v. 
10 cl1 i.c.v. 
20 pl i.c.v. 
Saline 
BIMU 1 
BIMU 8 
10 mlkg-’ p. o. 
60 mg*kg-t p. o. 
60 mg-kg-’ p. o 
3.2f0.4 
3.4xt.3 
3.txO.5 
3.4B.4 
3.1W.4 
3.5H.5 
3.6ti.4 
2.!9&0.5 
3.2N.4 
3.3kO.4 
3.5zbO.5 
3.5N.4 
3.4ti.5 
3.2H.5 
3.6M.3 
Number of falls (30 s) 
After treatment 
15 min 
1.9W.2 
1.4M.4 
1.5zI9.2 
2.8&0.5* 
1.3xl.3 
2.3ti.3 
3.6X).3* 
1.6fl.3 
2.3ti.4 
3.7ti.4* 
1.7Kl.3 
3.4x).4* 
2.8ztO.3 
2.5zbO.4 
2.799.2 
30 min 
l.lti.2 
l.lM.2 
1.2H.3 
2.3&0.4* 
l.lfl.3 
1.6fl.4 
2.5H.3* 
1 xkbo.4 
1.5Kl.3 
3.1x).5* 
1.2-10.3 
3.0?0.3* 
1.8Ht.4 
1.8fo.3 
1.3fo.3 
45 min 
0.9kO.2 
0.6kO.3 
0.6z!Sl.2 
1.3ti.3 
l.lM.2 
0.8ti.3 
1.4xl.4 
0.8M.3 
1.3ti.2 
2.8&0.3* 
1.3ti.3 
2.5ti.4* 
1.6M.3 
l.OHl.3 
1.4ti.3 
Each value represents the mean of 5 -10 mice. 
*P < 0.01 in comparison with saline controls. 
the rat paw-pressure test where the time-course reflected that observed with the hot-plate test 
(Fig. 1). In the paw-pressure test, no antinociception by BIMU 1 and BIMU 8 was detected in 
rats with bilateral lesions of the NBM (Table 2). In these rats cortical choline acetyltranferase 
activity was reduced by 55 f 6.1% (n=5) as compared with the sham operated rats. The 
antinociceptive effect of morphine (5 mg kg-’ i.p.) in the lesioned rats did not differ from that in 
the sham operated rats (Table 2). Finally, it should be noted that BIMU 1 and BIMU 8 elicited 
their antinociceptive effects without changing motor coordination as revealed by the rota-rod test 
where BIMU 1 and BlMU 8, administered s.c., i.c.v. and p.o. in an antinociceptive dose-range, 
did not increase the number of falls from the rotating rod (Table 3). Both compounds, at doses of 
50 mg kg-’ s.c., produced convulsions and 50% of the animals died. 
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Discussion 
BIMU 1 and BIMU 8 antinociception was elicited whichever noxious stimulus was used: thermal 
(hot-plate test), chemical (abdominal constriction test) and mechanical (paw pressure test). Doses 
which increase pain threshold were devoid of any other modification of animal behaviour. In 
fact, the motor coordination, evaluated by the mouse rota-rod test, was not modified by 
treatment with BIMU 1 and BIMU 8 at analgesic doses. 5-HT4 agonists antinociception was 
found to be dependent on a cholinergic activation as this analgesia is antagonized by the muscari- 
nit antagonist atropine, by the ACh depletor HC-3 and by lesion of the NBM which is the 
primary source of ACh for the cerebral cortex (33). Furthermore BIMU 1 and BIMU 8 exerted 
their antinociceptive effect by acting centrally since i.c.v. administration of the above-mentioned 
drugs were able to reduce the number of abdominal constrictions with the same intensity as that 
obtainable after S.C. or p.o. administration. Moreover, the antagonism exerted by i.c.v. injected 
HC-3 in mice and NBM lesions in rats on BIMU 1 and BIMU 8 induced antinociception, shows 
that the site of action of the two 5-HT4 agonists is centrally located. The integrity of the central 
cholinergic system is, therefore, fundamental for BIMU 1 and BIMU 8 antinociception. To this 
end, it is well known that direct or indirect cholinomimetics are able to increase pain threshold in 
both humans (34) and animals (12, 13, 14, 15, 16, 17, 18, 19, 20). A large difference exists 
between the analgesia induced in animals by both BIMU 1 and BIMU 8 and that induced by 
direct muscarinic agonists and cholinesterase inhibitors. In fact, while 5HT4 agonists produce 
antinociception without any visible side effect, the direct muscarinic agonists and the 
cholinesterase inhibitors provoke, at the same time, a clear cholinergic symptomatology (tremors, 
sialorrhoea, diarrhoea, lacrimation etc.). Other neurotransmitter systems did not appear to be 
involved in BIMU 1 and BIMU 8 antinociception since the opioid antagonist naloxone, the 
GABA, antagonist CGP 35348 and reserpine, were all unable to prevent 5-HT4 agonist-induced 
analgesic effect. The doses and administration schedules of the above-mentioned drugs were 
suitable for preventing antinociception induced respectively by morphine (23), GABA, agonist 
baclofen (35) and the antidepressant drugs clomipramine and amitriptyline (36). The prevention 
of BIMU 1 and BIMU 8 antinociception produced by the 5-HT4 antagonists SDZ 205-557 (37) 
and GR 125487 (38) suggests, moreover, that the central serotoninergic system exerts an 
excitatory tone on the cholinergic system. BIMU 1 and BIMU 8, by activating serotoninergic 
heteroreceptors, increase ACh release as well documented by microdialysis experiments (10). 
The results obtained have shown a good relationship between the antinociceptive effect of BIMU 
1 and BIMU 8 and the potentiation of cerebral ACh release described by Consolo et al. (10). In 
fact, the latency required to reach the maximum amplification of ACh release (20 min) by BIMU 
1 and BIMU 8 was equal to that required for reaching their antinociceptive peak (15 min). The 
fact that physostigmine was used in rats employed for ACh collection from the cerebral cortex but 
not in those used for antinociceptive tests, could explain the more lasting effects of BIMU 1 and 
BIMU 8 on ACh release as compared to antinociception. 
In summary our results have shown that BIMU 1 and BIMU 8 are able to induce antinociception 
by potentiating endogenous cholinergic activity. 
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